Facebook
Twitter
LinkedIn
ForwardOn The Horizon - The Future of Anti-Obesity Medications (Recorded)
Over the last decade, the FDA has approved five new medications for the treatment of obesity. The latest edition, semaglutide, published impressive weight loss results and we are just beginning. There is a rich pipeline of future anti-obesity medications (AOM) that will give provides excellent options for both the treatment of obesity and of the obesity-related diseases. This session will start with reviewing some of the common pathophysiologic pathways that current and future AOM’s target then discuss emerging and future prospects of pharmacotherapy for the treatment of obesity.
Recorded during Overcoming Obesity 2022.
CME/CE Expiration Date: 11/1/25
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Donna Ryan, MD, MABOM, FTOS
The Obesity Medicine Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.